" class="no-js "lang="en-US"> Carlo Montagner - Medtech Alert
Friday, December 01, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Carlo Montagner

Carlo Montagner

About Carlo Montagner

Carlo Montagner is the CEO and founder of Specialised Therapeutics Australia, an international biopharmaceutical company headquartered in Melbourne, Australia.

A highly experienced global pharmaceutical executive and entrepreneur, Carlo founded the company in 2007 to provide cutting edge healthcare products and technologies to patients in Australia, new Zealand and now, throughout South East Asia.

Prior to founding STA, he was the Los Angeles based president of global pharmaceutical company Abraxis Bioscience and is a former global head of oncology for Berlex Schering AG. He also held senior roles with Sanofi Aventis.

Related Story

Drug Development

 Global Sarcoma Therapy Now Approved For New Zealand Patients | MTA

Global Sarcoma Therapy Now Approved For New Zealand Patients

February 17 2023

Independent biopharmaceutical company, Specialised Therapeutics (ST), is pleased to announce that its portfolio therapy to […]

Diseases

 New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Now Available in the Philippines | Pharmtech Focus

New Early Breast Cancer Drug to Reduce Risk of Recurrence or Death Now Available in the Philippines

July 11 2022

A NEW drug shown to significantly reduce the risk of cancer recurrence or death in […]